Drug intelligence / Profile preview

chidamide + rituximab + polatuzumab vedotin

Development stage: Unknown
Lead developer: Tianjin Medical University Cancer Institute and Hospital
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

Chidamide + rituximab + polatuzumab vedotin (CRP regimen) is an investigational combination therapy being evaluated for the treatment of diffuse large B-cell lymphoma (DLBCL), specifically in elderly patients with previously untreated double-positive disease. The regimen combines chidamide, an oral subtype-selective histone deacetylase (HDAC) inhibitor; rituximab, a chimeric monoclonal antibody targeting CD20; and polatuzumab vedotin, an antibody-drug conjugate (ADC) targeting CD79b. This multi-modal approach aims to enhance anti-tumor activity through epigenetic modulation, antibody-dependent cellular cytotoxicity, and targeted delivery of the microtubule-disrupting agent monomethyl auristatin E (MMAE). The regimen is currently being studied in a Phase II clinical trial sponsored by Tianjin Medical University Cancer Institute and Hospital.

Brand names: PolivyRituxanMabTheraEpidaza
Other names: polatuzumab vedotin-Tianjin Medical University Cancer Institute and Hospital-diffuse large B-cell lymphoma

Targets

TUBB (Tubulin (alpha and beta subunits))CD20 (B-lymphocyte antigen CD20)HDAC (HDAC family)B-cell antigen receptor complex-associated protein beta chain

Beyond the preview

Go deeper on chidamide + rituximab + polatuzumab vedotin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chidamide + rituximab + polatuzumab vedotin.

Explore the full profile